Prevention of Rh(D) alloimmunization: a cost-benefit analysis.
The Rh Programme of Nova Scotia was established in 1964 for the prevention and treatment of Rh(D) alloimmunization. The program's effectiveness in preventing the condition has been established previously. Because of increasing budget restraint in health care we decided to examine the cost-effectiveness of the program by comparing the cost of prevention (office administration fees, program staff salaries and the price of Rh immune globulin) with the cost of health care services required in addition to standard obstetric procedures and neonatal care in 80 cases of Rh(D) alloimmunization treated from 1982 to 1986. Neonatal intensive care accounted for 80.1% of the additional health care expenses; an extra 512 hospital days for such care constituted 65.7% of the total treatment expense. The cost per case prevented ($1495) was 2.7 times less than the cost per case treated ($3986).
Baskett
T F
TF
Department of Obstetrics and Gynaecology, Dalhousie University, Halifax, NS.
Parsons
M L
ML
D002170:Canada; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage; D011247:Pregnancy; D012203:Rh Isoimmunization / Q000191:economics / Q000517:prevention & control*; D018029:Rho(D) Immune Globulin
D007136:Immunoglobulins; D018029:Rho(D) Immune Globulin